Patent · US Active

Proteasome inhibitors and methods of using the same

US9233115B2 · kind B2 · utility

0Cited by

31References

10Claims

0Family size

Assignee

Millennium Pharmaceuticals, Inc. · US

Inventors

Raffaella Bernardini · Calci, IT
Alberto Bernareggi · Vimercate, IT
Paolo G. Cassara · Monza, IT
Sankar Chatterjee · Lansdowne, US
Germano D'Arasmo · Novate Milanese, IT
Sergio De Munari · Milano, IT
Edmondo Ferretti · Ravenna, IT
Mohamed Iqbal · Malvern, US
Ernesto Menta · Parma, IT
Patricia A. Messina McLaughlin · Glen Mills, US
Ambrogio Oliva · Saronno, IT

Key dates

Filing date	Jul 24, 2013
Grant date	Jan 12, 2016
Priority date	—
Expiry date	Jul 24, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F5/025
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.